Atlas Trials

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Clinical trial NCT04775745 · RECRUITING

Trial details

NCT number
NCT04775745
Sponsor
Newave Pharmaceutical Inc
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
CLL/SLLWaldenstrom MacroglobulinemiaFollicular LymphomaDiffuse Large B Cell LymphomaMantle Cell LymphomaMarginal Zone LymphomaHairy Cell Leukemia
Start date
2021-07-19
Primary completion
2027-12-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.